11 July 2025 · Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
11 July 2025 · Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
11 July 2025 · New medicines have several protections against competition. Other factors influence availability of generics or biosimilars after loss of exclusivity.
4 July 2025 · Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.
9 April 2025 · An update supporting implementation of biosimilar and key generic medicines for aflibercept, golimumab, nilotinib and ferric carboxymaltose.
2 August 2024 · Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.
2 August 2024 · Ustekinumab biosimilars (Pyzchiva, Steqeyma, Uzpruvo, Wezenla) are licensed. Learn about indications, formulations, supporting evidence and differences.